Overview

Psilocybin for Major Depressive Disorder

Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to assess the effectiveness of psilocybin for the treatment of Major Depressive Disorder and potential therapeutic mechanisms. Enrolled participants will receive a single active dose of psilocybin, or a dose considered high enough to treat depression, administered orally with accompanying psychological support.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Psilocybin